Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05653752 · ClinicalTrials.gov registry record · Phase 1

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by MediLink Therapeutics (Suzhou) Co..

Active
Registry status
Phase 1
Development phase
80
Enrollment target
13
Study locations

NCT05653752 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 80 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05653752, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by MediLink Therapeutics (Suzhou) Co..

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
13
Study locations

Study Summary

This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.

Conditions Studied

Breast Cancer Non-Small Cell Lung Cancer

Interventions

  • DRUG YL202

Study Locations (13)

Texas

  • The University of Texas MD Anderson Cancer Center - Houston
  • Next Oncology-Dallas - Irving
  • UT health east Texas HOPE Cancer Center - Tyler

Zhejiang

  • The First Affiliated Hospital of Zhejiang University School of Medicine - Hangzhou
  • Zhejiang Cancer Hospital - Hangzhou
  • Taizhou Hospital of Zhejiang Province - Taizhou

Florida

  • BRCR Global - Plantation

Michigan

  • Karmanos Cancer Institute - Detroit

Virginia

  • Next Oncology-Virginia - Fairfax

Washington

  • Summit Cancer Center - Spokane Valley

Fujian

  • Fujian Cancer Hospital - Fuzhou

Hunan

  • Hunan Cancer Hospital - Changsha

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2022-12-20
Est. Completion 2026-12
Phase Phase 1

Sponsor

MediLink Therapeutics (Suzhou) Co.

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05653752

The ClinicalTrials.gov registry entry for NCT05653752 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is MediLink Therapeutics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which YL202 is the first listed.

NCT05653752 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Texas, Zhejiang, Florida.

Frequently Asked Questions

What is clinical trial NCT05653752 about?

NCT05653752 is a clinical study titled "A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer". This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor ...

What is the current status of trial NCT05653752?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2022-12-20. Estimated completion is 2026-12.

What conditions does trial NCT05653752 study?

This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT05653752?

The interventions under investigation include: YL202 (DRUG).

Who is sponsoring clinical trial NCT05653752?

This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05653752 being conducted?

This trial has 13 study locations across Florida, Michigan, Texas, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Non-Small Cell Lung Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.